Clinical Trials Logo

Filter by:
  • Recruiting  
  • « Prev · Page [2]
NCT ID: NCT03806452 Recruiting - Sickle Cell Disease Clinical Trials

SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

SIKAMIC
Start date: May 28, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this phase IIb, international, multicentre, double-blind, randomised, placebo-controlled study is to determine the effect of hydroxycarbamide on albuminuria after 6 months of treatment in SCD adult patients.

NCT ID: NCT03803735 Recruiting - Pediatric Cancer Clinical Trials

Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa

RFAOP
Start date: January 1, 2016
Phase:
Study type: Observational [Patient Registry]

The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group. This data will help to plan and provide correct pediatric oncology treatment and care for this population. Collecting the data will give much needed information on numbers, stage, treatment and outcome. The register will give data for local and national health authorities in planning pediatric cancer programs.

NCT ID: NCT03467958 Recruiting - Crohn Disease Clinical Trials

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Start date: August 24, 2018
Phase: Phase 3
Study type: Interventional

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.

NCT ID: NCT03464097 Recruiting - Crohn Disease Clinical Trials

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Start date: June 27, 2018
Phase: Phase 3
Study type: Interventional

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

NCT ID: NCT03352986 Recruiting - Sickle Cell Disease Clinical Trials

Substudy of CADRE: for People With Extreme Phenotype: BIOCADRE

BIOCADRE
Start date: May 15, 2017
Phase: N/A
Study type: Observational

BIOCADRE is a CADRE substudy and aims to characterize more precisely the sickle cell patients with extreme phenotype.

NCT ID: NCT03114137 Recruiting - Sickle Cell Disease Clinical Trials

Heart Arteries and Sickle Cell Disease / Coeur Artères DREpanocytose

CADRE
Start date: March 2012
Phase:
Study type: Observational [Patient Registry]

The CADRE study is a multinational observational cohort of patients with sickle-cell disease (SCD) in five west and central sub-Saharan African countries. The aim of this project is to describe the incidence and assess the predictive factors of SCD-related micro- and macro-vascular complications in sub-Saharan Africa.

NCT ID: NCT02251704 Recruiting - Malaria Clinical Trials

Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa

Start date: October 22, 2014
Phase: Phase 4
Study type: Interventional

This epidemiology study is planned to run in parallel with the EPI-MAL-002 and EPI-MAL-003 studies, enrolling from the same health and demographic surveillance system (HDSS) (or equivalent system) populations. The co-primary objectives are to produce longitudinal estimates of parasite prevalence in humans, and record malaria control measures usage in areas where EPI-MAL-002 and EPI-MAL-003 studies will take place.

NCT ID: NCT00216385 Recruiting - Tuberculosis Clinical Trials

A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis

Start date: January 2005
Phase: Phase 3
Study type: Interventional

Tuberculosis is currently treated with a 6-month course regimen. During this time many patients might fail to adhere to treatment and default, increasing the risk of recurrent disease which might be multidrug resistant. A shorter duration of treatment is expected to provide improved patient compliance and at least equal or better clinical outcome. The aim of the trial is to evaluate the efficacy and safety of a gatifloxacin-containing regimen of four months duration for the treatment of pulmonary tuberculosis,